Phio Pharmaceuticals Files 8-K: Material Agreement, Equity Sales
Ticker: PHIO · Form: 8-K · Filed: Jan 15, 2025 · CIK: 1533040
| Field | Detail |
|---|---|
| Company | Phio Pharmaceuticals Corp. (PHIO) |
| Form Type | 8-K |
| Filed Date | Jan 15, 2025 |
| Risk Level | medium |
| Pages | 6 |
| Reading Time | 7 min |
| Key Dollar Amounts | $0.0001, $3.00, $2.2 m, $25,000, $15,950 |
| Sentiment | neutral |
Sentiment: neutral
Topics: material-agreement, equity-sale, 8-k
TL;DR
Phio Pharma 8-K: New deal signed, equity sold. Watch closely.
AI Summary
On January 14, 2025, Phio Pharmaceuticals Corp. entered into a material definitive agreement. The company also reported on unregistered sales of equity securities and other events. This filing is a current report on Form 8-K.
Why It Matters
This 8-K filing indicates significant corporate activity for Phio Pharmaceuticals, including a new material agreement and equity transactions, which could impact its financial standing and strategic direction.
Risk Assessment
Risk Level: medium — The filing details material agreements and equity sales, which can introduce financial and operational risks for the company.
Key Players & Entities
- Phio Pharmaceuticals Corp. (company) — Registrant
- RXi Pharmaceuticals Corp (company) — Former company name
- January 14, 2025 (date) — Date of earliest event reported
FAQ
What is the nature of the material definitive agreement entered into by Phio Pharmaceuticals Corp. on January 14, 2025?
The filing states that Phio Pharmaceuticals Corp. entered into a material definitive agreement on January 14, 2025, but the specific details of this agreement are not provided in the excerpt.
What type of securities were sold in the unregistered sales of equity securities reported by Phio Pharmaceuticals Corp.?
The filing mentions unregistered sales of equity securities, but the specific type of securities and the terms of the sale are not detailed in the provided text.
What are the "Other Events" reported by Phio Pharmaceuticals Corp. in this 8-K filing?
The filing lists "Other Events" as a category, but the specific events are not described in the provided excerpt.
What is the principal executive office address for Phio Pharmaceuticals Corp.?
The principal executive offices of Phio Pharmaceuticals Corp. are located at 11 Apex Drive, Suite 300A, PMB 2006, Marlborough, Massachusetts 01752.
When did Phio Pharmaceuticals Corp. change its name from RXi Pharmaceuticals Corp?
Phio Pharmaceuticals Corp. changed its name from RXi Pharmaceuticals Corp on October 19, 2011.
Filing Stats: 1,712 words · 7 min read · ~6 pages · Grade level 12.1 · Accepted 2025-01-15 16:05:39
Key Financial Figures
- $0.0001 — h registered: Common Stock, par value $0.0001 per share PHIO The Nasdaq Capital M
- $3.00 — "Common Stock"), at a purchase price of $3.00 per share. Pursuant to the Securities P
- $2.2 m — the Private Placement are approximately $2.2 million, after deducting fees and estimat
- $25,000 — Offering and the Private Placement and $25,000 for non-accountable expenses, and $15,9
- $15,950 — 5,000 for non-accountable expenses, and $15,950 for clearing fees. In addition, the Com
- $3 — arrants have an exercise price equal to $3.75, or 125% of the offering price per s
Filing Documents
- phio_8k.htm (8-K) — 39KB
- phio_ex0401.htm (EX-4.1) — 112KB
- phio_ex0402.htm (EX-4.2) — 113KB
- phio_ex0501.htm (EX-5.1) — 8KB
- phio_ex1001.htm (EX-10.1) — 264KB
- phio_ex9901.htm (EX-99.1) — 13KB
- image_001.jpg (GRAPHIC) — 2KB
- 0001683168-25-000384.txt ( ) — 851KB
- phio-20250114.xsd (EX-101.SCH) — 3KB
- phio-20250114_lab.xml (EX-101.LAB) — 33KB
- phio-20250114_pre.xml (EX-101.PRE) — 24KB
- phio_8k_htm.xml (XML) — 4KB
02. Unregistered Sales of Equity Securities
Item 3.02. Unregistered Sales of Equity Securities. The disclosures in Item 1.01 of this Form 8-K regarding the Series H Warrants, the Warrant Shares, the Placement Agent Warrants and the shares of Common Stock issuable thereunder are incorporated by reference into this Item 3.02.
01. Other Events
Item 8.01. Other Events. On January 15, 2025 , the Company issued a press release announcing the pricing of the Registered Direct Offering and the Private Placement. The full text of the press releases is attached hereto as Exhibit 99.1 and incorporated herein by reference.
01. Financial Statements and Exhibits
Item 9.01. Financial Statements and Exhibits. (d) Exhibits. Number Description 4.1 Form of Series H Common Stock Warrant, dated January 15, 2025 . 4.2 Form of Placement Agent Warrant, dated January 15, 2025 . 5.1 Opinion of Hogan Lovells US LLP. 10.1 Form of Securities Purchase Agreement, dated January 14, 2025 , by and between the Company and each of the Purchasers signatory thereto. 23.1 Consent of Hogan Lovells US LLP (contained in Exhibit 5.1 ). 99.1 Press Release issued by the Company on January 15, 2025 . 104 Cover Page Interactive Data File (embedded within the Inline XBRL document). 3
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. PHIO PHARMACEUTICALS CORP. Date: January 15, 2025 By: /s/ Robert Bitterman Robert Bitterman President & Chief Executive Officer 4